Inventiva (IVA) Competitors

Inventiva (NASDAQ:IVA) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.

Do analysts recommend IVA or NUVB?

Inventiva currently has a consensus target price of $10.40, suggesting a potential upside of 167.35%. Nuvation Bio has a consensus target price of $7.83, suggesting a potential upside of 267.76%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Do insiders and institutionals have more ownership in IVA or NUVB?

19.1% of Inventiva shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 29.9% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has preferable earnings & valuation, IVA or NUVB?

Nuvation Bio has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$9.20M	22.19	-$119.51M	N/A	N/A
Nuvation Bio	$7.87M	91.63	-$75.80M	-$2.26	-0.94

Which has more risk & volatility, IVA or NUVB?

Inventiva has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Does the media prefer IVA or NUVB?

In the previous week, Nuvation Bio had 6 more articles in the media than Inventiva. MarketBeat recorded 9 mentions for Nuvation Bio and 3 mentions for Inventiva. Nuvation Bio's average media sentiment score of 0.77 beat Inventiva's score of 0.66 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in IVA or NUVB?

Nuvation Bio received 32 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 81.16% of users gave Nuvation Bio an outperform vote.

Company	Underperform	Outperform
Inventiva	Outperform Votes 24 82.76%	Underperform Votes 5 17.24%
Nuvation Bio	Outperform Votes 56 81.16%	Underperform Votes 13 18.84%

Is IVA or NUVB more profitable?

Inventiva's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Nuvation Bio	N/A	-21.89%	-17.86%

Summary

Nuvation Bio beats Inventiva on 11 of the 16 factors compared between the two stocks.